No Data
RAAS Blood Products to Buy Back Up to 500 Million Yuan Shares
Shanghai RAAS Blood Products (002252.SZ) plans to repurchase company shares for 0.25 billion to 0.5 billion yuan.
Shanghai RAAS Blood Products (002252.SZ) announced that the company plans to use its own or self-raised funds for centralized bidding Trade...
Express News | Shanghai Raas Blood Products Says Bank Agrees to Provide Controlling Shareholder 450 Mln Yuan in Loans for Boosting Holdings in Company
Shanghai RAAS Blood Products (002252.SZ): The controlling Shareholder's Shareholding in the company has obtained a commitment letter for a special loan.
On January 12, Gelonghui reported that Shanghai RAAS Blood Products (002252.SZ) announced that it recently received a notification from its controlling shareholder Haiyingkang. Haiyingkang obtained a "Loan Commitment Letter from Agricultural Bank of China" issued by the Qingdao branch of Agricultural Bank of China (hereinafter referred to as "Agricultural Bank"). Under the premise of meeting relevant loan conditions, Agricultural Bank agreed to provide loan support to Haiyingkang, with a loan amount of 0.45 billion yuan, a loan term of 3 years, and the loan purpose limited to increasing the Shareholding in Shanghai RAAS Blood Products. The commitment letter is valid for 1 year from the date of issuance. Specific loan matters will be agreed upon in the relevant contract.
Shanghai RAAS Blood Products (002252.SZ): The controlling Shareholder plans to increase its Shareholding by 0.25 billion yuan to -0.5 billion yuan in the company's shares.
On January 8, Gelonghui reported that Shanghai RAAS Blood Products (002252.SZ) announced that it received a notice from its controlling shareholder Haiyingkang (Qingdao) Medical Technology Co., Ltd. (referred to as "Haiyingkang"), informing that Haiyingkang increased its shareholding in the company by a total of 22,933,800 shares through centralized bidding trading on January 7 and 8, 2025, accounting for 0.35% of the company's total share capital, with an increase amount of 155.8467 million yuan (referred to as "first increase"), and plans to increase its shareholding within six months from the date of this announcement (except for legal, regulatory, and Shenzhen Stock Exchange business rules that prohibit further shareholding increase).
Qingdao Haier Biomedical Co., Ltd.'s merger plan for "Blood King" has failed.
A specific plan recognized by all relevant parties could not be formed.
